Who are Disitamab Vedotin Injection （18 weeks）'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): [89Zr]Zr-crefmirlimab berdoxam, Venetoclax; Rituximab, Hympavzi, Beyfortus, Praxbind, Darzalex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/disitamab-vedotin-injection-18-weeks.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Disitamab Vedotin Injection （18 weeks） — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disitamab Vedotin Injection （18 weeks） (Disitamab Vedotin Injection （18 weeks）) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology.

phase 2 Monoclonal antibody CD6 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Disitamab Vedotin Injection （18 weeks） (Disitamab Vedotin Injection （18 weeks）) — RemeGen Co., Ltd.. Anti-CD6 monoclonal antibody

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Disitamab Vedotin Injection （18 weeks） TARGET	Disitamab Vedotin Injection （18 weeks）	RemeGen Co., Ltd.	phase 2	Monoclonal antibody	CD6
[89Zr]Zr-crefmirlimab berdoxam	89zr-zr-crefmirlimab-berdoxam	Pfizer	marketed	Radiolabeled Monoclonal Antibody	Fibroblast Activation Protein (FAP)	Not specified
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A
Hympavzi	MARSTACIMAB	Pfizer Inc	marketed	Monoclonal Antibody	Factor Xa	2025-01-01
Beyfortus	NIRSEVIMAB	AstraZeneca	marketed	Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]	RSV	2023-01-01
Praxbind	IDARUCIZUMAB	Boehringer Ingelheim	marketed	Humanized Monoclonal Antibody Fragment [EPC]	dabigatran and its acylglucuronide metabolites	2015-01-01
Darzalex	daratumumab	Johnson & Johnson	marketed	Monoclonal antibody	CD38	2015-01-01

Recent regulatory actions (last 90 days)

2026-04-07 — Beyfortus · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Disitamab Vedotin Injection （18 weeks） — Competitive Intelligence Brief. https://druglandscape.com/ci/disitamab-vedotin-injection-18-weeks. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab